title: Adoptive immunotherapy of ovarian carcinoma with bs-MAb-targeted lymphocytes: a multicenter study.
abstract: A bispecific monoclonal antibody (bs-MAb) (OC/TR) was produced in large quantities for the intraperitoneal (i.p.) treatment of ovarian cancer. The bs-MAb recognizes the folate-binding protein on ovarian cancer cells on the one hand and the CD3 activation site on T lymphocytes on the other. T lymphocytes were expanded ex vivo, targeted with OC/TR in vitro and administered to the i.p. cavity in the presence of soluble OC/TR. All patients developed human anti-mouse-antibodies (HAMA). In the Dutch study, 2 complete remissions (CR) were seen, 2 partial regressions (PR), I stable disease (SD) and I progressive disease (PD). In the Italian study 3 CR, I PR, I SD and 2 PD were seen.
authors.affiliation: Department of Clinical and Tumor Immunology, Daniel den Hoed Cancer Center, Rotterdam, The Netherlands.
authors.forename: R L
authors.initials: RL
authors.lastname: Bolhuis
authors.forename: C H
authors.initials: CH
authors.lastname: Lamers
authors.forename: S H
authors.initials: SH
authors.lastname: Goey
authors.forename: A M
authors.initials: AM
authors.lastname: Eggermont
authors.forename: J B
authors.initials: JB
authors.lastname: Trimbos
authors.forename: G
authors.initials: G
authors.lastname: Stoter
authors.forename: A
authors.initials: A
authors.lastname: Lanzavecchia
authors.forename: E
authors.initials: E
authors.lastname: di Re
authors.forename: S
authors.initials: S
authors.lastname: Miotti
authors.forename: F
authors.initials: F
authors.lastname: Raspagliesi
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000917:Antibody Formation; D003602:Cytotoxicity, Immunologic; D005260:Female; D006801:Humans; D016219:Immunotherapy, Adoptive; D007376:Interleukin-2 / Q000627:therapeutic use*; D008213:Lymphocyte Activation; D010051:Ovarian Neoplasms / Q000628:therapy*; D013601:T-Lymphocytes / Q000276:immunology*
chemical_list: D000911:Antibodies, Monoclonal; D007376:Interleukin-2